company background image
43 logo

electroCore DB:43E0 Stock Report

Last Price

€3.67

Market Cap

€29.2m

7D

0%

1Y

-15.3%

Updated

16 May, 2023

Data

Company Financials +

43 Stock Overview

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.

43 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

electroCore, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for electroCore
Historical stock prices
Current Share PriceUS$3.67
52 Week HighUS$9.96
52 Week LowUS$2.50
Beta1.21
1 Month Change0%
3 Month Change-13.44%
1 Year Change-15.30%
3 Year Change-70.37%
5 Year Changen/a
Change since IPO-97.98%

Recent News & Updates

Recent updates

Shareholder Returns

43DE Medical EquipmentDE Market
7D0%2.4%2.5%
1Y-15.3%7.2%7.0%

Return vs Industry: 43E0 underperformed the German Medical Equipment industry which returned -2.5% over the past year.

Return vs Market: 43E0 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 43's price volatile compared to industry and market?
43 volatility
43 Average Weekly Movementn/a
Medical Equipment Industry Average Movement5.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 43E0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 43E0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200562Dan Goldbergerhttps://www.electrocore.com

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults; Truvaga for the support of general health and wellbeing; and TAC-STIM, a form of nVNS for human performance. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.

electroCore, Inc. Fundamentals Summary

How do electroCore's earnings and revenue compare to its market cap?
43 fundamental statistics
Market cap€29.25m
Earnings (TTM)-€20.66m
Revenue (TTM)€8.72m

3.4x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
43 income statement (TTM)
RevenueUS$9.47m
Cost of RevenueUS$1.48m
Gross ProfitUS$8.00m
Other ExpensesUS$30.45m
Earnings-US$22.45m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.73
Gross Margin84.43%
Net Profit Margin-236.96%
Debt/Equity Ratio0%

How did 43 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.